NCT02253745View on ClinicalTrials.gov

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
ADHD
Interventions
DRUG

V81444

V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14

DRUG

Placebo

Capsules to match V81444 twice daily for 13 days and once on Day 14

Trial Locations (1)

66212

Vince and Associates Clinical Research, Kansas City

All Listed Sponsors
lead

Vernalis (R&D) Ltd

INDUSTRY

NCT02253745 - Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter